RESUMO
BACKGROUND: Rapid identification of causative bacteria in treatment of acute otitis media (AOM) is of paramount importance for appropriate antibiotic use. MATERIALS AND METHODS: This prospective observational study was conducted in 15 hospitals and clinics in Japan between 2018 and 2020. A new rapid antigen test kit (AOS-116), which simultaneously detects antigens for Streptococcus pneumoniae (Sp) and Haemophilus influenzae (Hi), was applied for middle ear fluids (MEFs) and nasopharyngeal secretions (NPSs) in patients with moderate to severe AOM. We investigated relationship between the results of rapid test, severity at initial visit, and clinical course. RESULTS: Regarding performance accuracy based on culture results, AOS-116 showed 1) high (>80%) sensitivity, specificity, and negative predictive value (NPV) in MEFs for both antigens, 2) high sensitivity, specificity, and positive predictive value (PPV) in NPSs for Hi antigen, and 3) high specificity, and PPV in NPSs for Sp antigen. Regarding predictive value of nasopharyngeal culture and antigen detection for causative middle ear pathogens, similar results were observed between AOS-116 and culture, which was characterized with high sensitivity and NPV for both pathogens. MEFs/NPSs positive for Hi antigen were significantly associated with eardrum findings, and severity. MEFs/NPSs positive for pneumococcal antigen were significantly associated with severity of otalgia, fever, and otorrhea. Among patients with prior antimicrobial treatment, improvement tended to be slower in cases positive for Hi than in cases negative. CONCLUSION: The rapid antigen detection test is useful as a decision-making tool for prescribing antimicrobial agents and may play an important role in promoting appropriate antimicrobial use.
RESUMO
OBJECTIVE: To assess the efficacy, safety, and tissue penetration of solithromycin for the treatment of otorhinolaryngological infections, we conducted three studies: a tissue penetration study with patients scheduled to undergo otorhinolaryngological tissue removal, an open-label study comprising patients with otitis media, pharyngitis, laryngitis, and tonsillitis, and a non-inferiority study compared with high-dose cefcapene-pivoxil (CFPN-PI). METHODS: Tissue penetration study; 17 patients with chronic rhinosinusitis, chronic otitis media, chronic tonsillitis, or palatine tonsillar hypertrophy, who required resection or removal of their tissue, were enrolled. Solithromycin was administered orally, and otorhinolaryngological tissues were collected 3.5-6 h after drug administration; blood was collected within 15 min before and after drug administration. The collected tissues and blood concentrations were measured at a central laboratory. Open-label study; 55 patients who were diagnosed with acute otitis media, laryngopharyngitis, or tonsillitis were enrolled. Solithromycin was administered orally 800 mg on Day 1, while on days 2-7, 400 mg of the drug was administered once daily. The primary endpoint is the clinical response at Test-of-Cure (TOC: 5-10 days after completion) Non-inferiority study; 283 patients with acute rhinosinusitis or acute exacerbation of chronic rhinosinusitis were randomized into either the solithromycin group or CFPN-PI group. Solithromycin was administered 800 mg once daily on Day 1 and 400 mg once daily while on Days 2-7 in solithromycin group, and CFPN-PI was administered 150 mg three times a day while on Days 1-7 in CFPN-PI group. The primary endpoint is the clinical response at TOC. RESULTS: In the tissue penetration study, the tissue concentration ratios (tissue concentration/plasma concentration) of solithromycin were 4.19 in the sinonasal mucosa, 1.33 in the middle ear mucosa, and 6.12 in the palatine tonsil tissue. In the open-label study, the efficacy rates at the TOC were 97.0 % for acute otitis media, 100 % for laryngopharyngitis, and 81.8 % for tonsillitis. In the non-inferiority study comprising patients with rhinosinusitis, the efficacy rate at the TOC was 87.7 % for solithromycin and 89.7 % for CFPN-PI. The difference in the efficacy rate (95 % confidence interval) was -2.0 % (-9.4 % to 5.4 %), verifying the non-inferiority of solithromycin to CFPN-PI. The most common adverse events in patients administered solithromycin were diarrhea (20.7 %), nausea and nasopharyngitis (3.6 %,), pharyngitis and elevated hepatic function test results (3.1 %), and abnormal hepatic function (2.1 %). CONCLUSION: Based on the findings, it is suggested that solithromycin is useful for the treatment of otorhinolaryngological infections.
Assuntos
Laringite , Macrolídeos , Otite Média , Faringite , Tonsilite , Triazóis , Humanos , Antibacterianos/uso terapêutico , Japão , Cefalosporinas/uso terapêutico , Faringite/tratamento farmacológico , Tonsilite/tratamento farmacológico , Otite Média/tratamento farmacológico , Laringite/tratamento farmacológicoRESUMO
OBJECTIVE: "Clinical Practice Guidelines for the Diagnosis and Management of Acute Otitis Media in Children-2018 update (2018 Guidelines)" aim to provide appropriate recommendations about the diagnosis and management of children with acute otitis media (AOM), including recurrent acute otitis media (recurrent AOM), in children under 15 years of age. These evidence-based recommendations were created with the consensus of the subcommittee members, taking into consideration unique characteristics of bacteriology and antimicrobial susceptibilities of AOM pathogens in Japan, as well as global advances in vaccines. METHODS: The subcommittee re-evaluated key clinical issues based on SCOPE (a master plan of the guidelines) and created clinical questions (CQ) about the diagnosis and management of AOM patients. A literature search of the publications from 2013 to 2016 were added to the Guidelines 2013, not only to assess the evidence on the effectiveness of vaccines, but also to provide up to date information of the bacteriology and antimicrobial susceptibilities of AOM causative pathogens in Japan. RESULTS: We have proposed guidelines for disease severity-based management of AOM patients, after classifying AOM severity into mild, moderate, and severe, based on age, clinical manifestations, and otoscopic findings. CONCLUSIONS: Precise otoscopic findings are essential for judging AOM severity, which can lead to appropriate management of AOM patients.
Assuntos
Antibacterianos/uso terapêutico , Otite Média/diagnóstico , Otite Média/terapia , Guias de Prática Clínica como Assunto , Adolescente , Criança , Pré-Escolar , Gerenciamento Clínico , Resistência Microbiana a Medicamentos , Humanos , Lactente , Recém-Nascido , Japão , Otoscopia , Recidiva , Índice de Gravidade de Doença , Conduta ExpectanteRESUMO
OBJECTIVE: To (1) indicate the definition, the disease state, methods of diagnosis, and testing for otitis media with effusion (OME) in childhood (<12 years); and (2) recommend methods of treatment in accordance with the evidence-based consensus reached by the Subcommittee of Clinical Practice Guideline for Diagnosis and Management of OME in Children. METHODS: We produced Clinical Questions (CQs) concerning the treatment of OME and searched the literature published until April 2014 according to each theme including CQ, the definition, the disease state, the method of diagnosis, and examination. The recommendations are based on the results of the literature review and the expert opinion of the Subcommittee. RESULTS: Because children with Down's syndrome and cleft palate are susceptible to OME, we categorized OME into low-risk and high-risk groups (e.g., Down's syndrome and cleft palate), and recommended the appropriate treatment for each group. CONCLUSION: In the clinical management of OME in children, Japanese Clinical Practice Guidelines recommend management not only of OME itself, such as effusion in the middle ear and pathological changes in the tympanic membrane, but also pathological abnormality in surrounding organs, such as infectious or inflammatory diseases.
Assuntos
Otite Média com Derrame/diagnóstico , Otite Média com Derrame/terapia , Testes de Impedância Acústica , Adenoidectomia , Algoritmos , Antibacterianos/uso terapêutico , Anti-Infecciosos Locais/uso terapêutico , Audiometria de Tons Puros , Carbocisteína/uso terapêutico , Perda Auditiva/etiologia , Humanos , Japão , Ventilação da Orelha Média , Otoscopia , Seios Paranasais/patologia , Pediatria , Osso Temporal/diagnóstico por imagem , Conduta ExpectanteRESUMO
OBJECTIVE: To (1) indicate methods of diagnosis and testing for childhood (<15 years) acute otitis media (AOM) and (2) recommend methods of treatment in accordance with the evidence-based consensus reached by the Subcommittee of Clinical Practice Guideline for Diagnosis and Management of AOM in Children (Subcommittee of Clinical Practice Guideline), in light of the causative bacteria and their drug sensitivity of AOM in Japan. METHODS: We investigated the most recently detected bacteria causing childhood AOM in Japan as well as antibacterial sensitivity and the worldwide distinct progress of vaccination, produced Clinical Questions concerning the diagnosis, testing methods, and treatment of AOM, searched literature published during 2000-2004, and issued the 2006 Guidelines. In the 2009 and 2013 Guidelines, we performed the same investigation with the addition of literature, which were not included in the 2006 Guidelines and published during 2005-2008 and during 2009-2012, respectively. RESULTS: We categorized AOM as mild, moderate, or severe on the basis of tympanic membrane findings and clinical symptoms, and presented recommended treatment for each degree of severity. CONCLUSION: Accurate assessment of tympanic membrane findings is important for judging the degree of severity and selecting a method of treatment. Some of new antimicrobial agents and pneumococcal vaccination are recommended as new treatment options.
Assuntos
Antibacterianos/uso terapêutico , Infecções por Haemophilus/tratamento farmacológico , Otite Média/tratamento farmacológico , Infecções Pneumocócicas/tratamento farmacológico , Guias de Prática Clínica como Assunto , Membrana Timpânica/patologia , Doença Aguda , Adolescente , Criança , Pré-Escolar , Técnicas de Diagnóstico Otológico , Infecções por Haemophilus/diagnóstico , Humanos , Lactente , Japão , Otite Média/diagnóstico , Otite Média/prevenção & controle , Otoscopia , Infecções Pneumocócicas/diagnóstico , Infecções Pneumocócicas/prevenção & controle , Vacinas Pneumocócicas/uso terapêutico , Índice de Gravidade de DoençaAssuntos
Rinite/tratamento farmacológico , Sinusite/tratamento farmacológico , Doença Aguda , Adolescente , Adulto , Humanos , JapãoRESUMO
Cochlear nerve deficiency (CND) is diagnosed with magnetic resonance imaging (MRI) by an absent or small cochlear nerve. A small or absent bony cochlear nerve canal (BCNC) detected with computed tomography (CT) has been also considered as CND. We reviewed five bilateral hearing impaired children with BCNC. All patients were born maturely at full-term birth. Two of them had undergone newborn hearing screening (NHS), one passed and the other was referred in only one ear. Among five children, only one had a small internal auditory canal (IAC) diagnosed with CT. Two children with intracranial abnormalities also had cochlear anomalies without a small IAC. Hearing aids showed some effectiveness in two patients with normal-sized IACs, and they could communicate with normal speech using hearing aids. One with a small-sized IAC was unable to communicate with speech using hearing aids. The efficacy of hearing aids in the other 2 patients has not been evaluated yet. We concluded that patients with small or absent BCNCs showed various audiometorical findings and clinical courses.
Assuntos
Nervo Coclear/anormalidades , Perda Auditiva/cirurgia , Pré-Escolar , Implantes Cocleares , Nervo Coclear/fisiopatologia , Constrição Patológica/diagnóstico por imagem , Orelha Interna/patologia , Feminino , Perda Auditiva/congênito , Perda Auditiva/diagnóstico , Perda Auditiva Central/diagnóstico , Perda Auditiva Central/etiologia , Perda Auditiva Central/terapia , Humanos , Lactente , Imageamento por Ressonância Magnética , Tomografia Computadorizada por Raios X , Resultado do TratamentoRESUMO
Out of 175 pneumococcal isolates from middle ear fluids, 26.3% were penicillin-resistant S. pneumoniae (PRSP). Serotypes 19F and 23F occurred most frequently among PRSP strains. The 7-valent pneumococcal conjugate vaccine (PCV) showed better coverage of PRSP strains (87.0%). The 7-valent PCV may reduce the prevalence of PRSP in Japan.
Assuntos
Orelha Média/microbiologia , Exsudatos e Transudatos/microbiologia , Otite Média/microbiologia , Resistência às Penicilinas , Infecções Pneumocócicas/microbiologia , Streptococcus pneumoniae/classificação , Streptococcus pneumoniae/efeitos dos fármacos , Antibacterianos/farmacologia , Criança , Pré-Escolar , Vacina Pneumocócica Conjugada Heptavalente , Humanos , Lactente , Japão/epidemiologia , Penicilinas/farmacologia , Infecções Pneumocócicas/epidemiologia , Vacinas Pneumocócicas/imunologia , Sorotipagem , Streptococcus pneumoniae/isolamento & purificaçãoRESUMO
To evaluate the efficacy and safety of CLAVAMOX dry syrup (potassium clavulanate/amoxicillin) in children with otitis media, we conducted a postmarketing surveillance from February to September 2006. The analysis was made on the basis of 470 survey sheets collected from 127 medical institutions, of which we investigated 455 cases for safety, and 433 cases for efficacy. The efficacy was 95.2% in the 433 subjects eligible for the efficacy analysis. The clinical improvement rates for major symptoms (otalgia, otorrhea, flare reaction of drum membrane and fever) were 95% or more. The efficacies for the three major offending bacteria of otitis media (Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis) were between 94.6% and 100%. The efficacies for penicillin-resistant Streptococcus pneumoniae (PRSP) and penicillin intermediate resistant Streptococcus pneumoniae (PISP) were 95% or more. Adverse drug reactions (ADRs) were reported in 106 (23.3%) of the 455 subjects eligible for safety analysis. The major ADRs were diarrhea, of which incident was 22.6% (103 of 455). These ADRs were observed at a higher rate in younger age patients. Most of the diarrhea cases were non-serious, reversible on discontinuation or continuation of the drug. No clinically important serious diarrhea cases such as pseudomembranous colitis or dehydration were observed. Our surveillance results demonstrated that CLAVAMOX dry syrup had excellent efficacy and clinically manageable safety in children with otitis media. These findings indicated that this medicine was clinically-useful in children with otitis media.
Assuntos
Combinação Amoxicilina e Clavulanato de Potássio/administração & dosagem , Combinação Amoxicilina e Clavulanato de Potássio/efeitos adversos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Otite Média/tratamento farmacológico , Vigilância de Produtos Comercializados/métodos , Criança , Pré-Escolar , Formas de Dosagem , Feminino , Haemophilus influenzae/isolamento & purificação , Humanos , Lactente , Masculino , Moraxella catarrhalis/isolamento & purificação , Otite Média/microbiologia , Estudos Prospectivos , Streptococcus pneumoniae/isolamento & purificaçãoRESUMO
Kawasaki disease (KD) is an acute systemic vasculitis syndrome of infants and young children. Although its etiology is largely unknown, epidemiological findings suggest that genetic factors play a role in the pathogenesis of KD. To identify genetic factors, affected sib-pair analysis has been performed. One of the identified peaks was located on the Xq26 region. A recent report of elevated expression of CD40 ligand (CD40L), which maps to Xq26, during the acute-phase KD, and its relationship to the development of coronary artery lesions (CAL) prompted us to screen for polymorphism of CD40L and to study the association of the gene to KD. A newly identified SNP in intron 4 (IVS4+121 A>G) is marginally over-represented in KD patients as compared to controls (109/602, 18.1 vs 111/737, 15.1%). When male KD patients with CAL were analyzed as a patient group, the SNP was significantly more frequent than in controls (15/58, 25.9%, vs 111/737, 15.1%, OR=2.0, 95% CI=1.07-3.66; P=0.030). Interestingly, this variation was extremely rare in a control Caucasian population (1/145, 0.7%). Our results suggest a role of CD40L in the pathogenesis of CAL and might explain the excess of males affected with KD.